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Abstract

Key Points

IMPORTANCE The US Preventive Services Task Force (USPSTF) released updated lung cancer
screening recommendations in 2021, lowering the screening age from 55 to 50 years and smoking
history from 30 to 20 pack-years. These changes are expected to expand screening access to women
and racial and ethnic minority groups.

Question Is the updated US Preventive
Services Task Force (USPSTF)
recommendations for lung cancer
screening associated with a clinically
meaningful change in the distribution of

OBJECTIVE To estimate the population-level changes associated with the 2021 USPSTF expansion
of lung cancer screening eligibility by sex, race and ethnicity, sociodemographic factors, and

the characteristics of individuals who
are eligible for screening?
Findings In this cohort study using data

comorbidities in 5 community-based health care systems.

derived from 5 health care systems, the

DESIGN, SETTING, AND PARTICIPANTS This cohort study analyzed data of patients who received

updated 2021 USPSTF

care from any of 5 community-based health care systems (which are members of the Population-

recommendations were associated with

based Research to Optimize the Screening Process Lung Consortium, a collaboration that conducts

an increased overall proportion of

research to better understand how to improve the cancer screening processes in community health

women, racial and ethnic minority

care settings) from January 1, 2010, through September 30, 2019. Individuals who had complete

groups, and individuals with lower

smoking history and were engaged with the health care system for 12 or more continuous months

socioeconomic status who are eligible

were included. Those who had never smoked or who had unknown smoking history were excluded.

for lung cancer screening.
Meaning The 2021 USPSTF

EXPOSURES Electronic health record–derived age, sex, race and ethnicity, socioeconomic status
(SES), comorbidities, and smoking history.

recommendations for lung cancer
screening eligibility are expected to
enhance opportunities for community-

MAIN OUTCOMES AND MEASURES Differences in the proportion of the newly eligible population
by age, sex, race and ethnicity, Charlson Comorbidity Index, chronic obstructive pulmonary disease
diagnosis, and SES as well as lung cancer diagnoses under the 2013 recommendations vs the
expected cases under the 2021 recommendations were evaluated using χ2 tests.

based programs to reduce barriers to
lung cancer screening access for
individuals who are at highest risk for
lung cancer.

RESULTS As of September 2019, there were 341 163 individuals aged 50 to 80 years who currently
or previously smoked. Among these, 34 528 had electronic health record data that captured packyear and quit-date information and were eligible for lung cancer screening according to the 2013
USPSTF recommendations. The 2021 USPSTF recommendations expanded screening eligibility to
18 533 individuals, representing a 53.7% increase. Compared with the 2013 cohort, the newly eligible

+ Invited Commentary
+ Supplemental content
Author affiliations and article information are
listed at the end of this article.

2021 population included 5833 individuals (31.5%) aged 50 to 54 years, a larger proportion of
women (52.0% [n = 9631]), and more racial or ethnic minority groups. The relative increases in the
proportion of newly eligible individuals were 60.6% for Asian, Native Hawaiian, or Pacific Islander;
67.4% for Hispanic; 69.7% for non-Hispanic Black; and 49.0% for non-Hispanic White groups. The
relative increase for women was 13.8% higher than for men (61.2% vs 47.4%), and those with a lower
comorbidity burden and lower SES had higher relative increases (eg, 68.7% for a Charlson
(continued)
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Abstract (continued)

Comorbidity Index score of 0; 61.1% for lowest SES). The 2021 recommendations were associated
with an estimated 30% increase in incident lung cancer diagnoses compared with the 2013
recommendations.
CONCLUSIONS AND RELEVANCE This cohort study suggests that, in diverse health care systems,
adopting the 2021 USPSTF recommendations will increase the number of women, racial and ethnic
minority groups, and individuals with lower SES who are eligible for lung cancer screening, thus
helping to minimize the barriers to screening access for individuals with high risk for lung cancer.
JAMA Network Open. 2021;4(10):e2128176. doi:10.1001/jamanetworkopen.2021.28176

Introduction
On March 9, 2021, the US Preventive Services Task Force (USPSTF) released guidelines that updated
its 2013 recommendations for annual lung cancer screening with low-dose computed tomography
and lowered the screening starting age from 55 to 50 years and minimum smoking history from 30 to
20 pack-years. The 2013 USPSTF recommendations were informed by criteria used in the National
Lung Screening Trial (NLST), which reported that screening with low-dose computed tomography
reduced lung cancer mortality by 20% in trial participants who were at an increased risk for lung
cancer.1 In response to the NLST findings and 2013 USPSTF recommendations, community health
systems across the United States began implementing lung cancer screening programs. Estimates of
the uptake of lung cancer screening, however, remain low, and early experience suggests that the
outcomes associated with lung cancer screening in community settings may differ from those
experienced by NLST participants in part because of differences in the characteristics of the
individuals who receive care in community health care systems.2-6
Previous research also suggested that when the 2013 USPSTF recommendations were applied
in community health care settings, they may have exacerbated existing disparities in lung cancer
diagnosis and outcomes, particularly among women, racial and ethnic minority groups, and those in
the lowest socioeconomic status (SES) categories.7-10 Analyses conducted by the Cancer
Intervention and Surveillance Modeling Network (CISNET) Lung Cancer Working Group estimated
that the 2021 USPSTF recommendations could increase the screening-eligible population by 87% as
well as the relative proportion of women by 96%, non-Hispanic Black individuals by 106%, Hispanic
individuals by 112%, and Asian individuals by 61%.11 Moreover, CISNET estimated that the number of
screening-detected lung cancers could increase by 21%.11
The CISNET models and the systematic evidence review that informed the 2021 USPSTF
recommendations were both based largely on clinical trial findings.11,12 However, it is unknown how
these changes in recommendations will affect community-based screening programs that serve
diverse populations in heterogeneous settings. The estimated population impact of the 2021 USPSTF
recommendations that was calculated by CISNET was also based on survey data, which were limited
by potential sampling bias and misclassification of diagnostic vs screening scans.13,14 In this cohort
study, we estimated the population-level changes associated with the 2021 USPSTF expansion of
lung cancer screening eligibility by age, sex, race and ethnicity, sociodemographic factors, and
comorbidities within 5 community-based health care systems. In addition, we compared the
proportion of individuals with an incident lung cancer diagnosis under the 2013 USPSTF
recommendations with the estimated number of incident cases under the 2021 USPSTF criteria.
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Methods
Study Population and Setting
This cohort study was conducted within the Population-based Research to Optimize the Screening
Process (PROSPR) Lung Consortium, a collaboration of 5 diverse health care systems in the US
(Henry Ford Health System, Detroit, Michigan; Kaiser Permanente Colorado, Aurora, Colorado; Kaiser
Permanente Hawaii, Oahu, Hawaii; Marshfield Clinic Health System, Marshfield, Wisconsin; and the
University of Pennsylvania Health System, Philadelphia, Pennsylvania) that conducts research to
better understand how to improve the cancer screening processes in community health care
settings.4,15 The PROSPR Lung Consortium developed a retrospective cohort of patients aged 35 to
89 years who engaged with any of these 5 health care systems from January 1, 2010, through
September 30, 2019. This study followed Strengthening the Reporting of Observational Studies in
Epidemiology (STROBE) reporting guideline and was approved by the Kaiser Permanente Colorado
Institutional Review Board, which waived the informed consent requirement because this
observational study presented minimal risks to the participants whose data were analyzed.

Data Sources and Cohort Identification
The PROSPR Lung Consortium common data model includes harmonized data on patient sex, race
and ethnicity, smoking history, procedures, diagnoses, cancer registry, and Census tract-based
measures of SES that were derived from each health care system’s administrative, electronic health
record (EHR), and claims systems. To address variations of the changes associated with the 2021
USPSTF recommendations in the PROSPR Lung Consortium population compared with the CISNET
estimates, we obtained self-reported measures of race and ethnicity from the individual patient's
EHR. As shown in the Figure, we initially identified 2 overlapping cohorts of patients within the
common data model who had complete smoking history and were engaged with the health care
system for 12 or more continuous months as of September 30, 2019; we excluded those who had
never smoked or who had unknown smoking history.
Specifically, the eligible cohort under the 2013 USPSTF recommendations included individuals
aged 55 to 80 years who had at least a 30 pack-year smoking history and currently smoked or quit
within the past 15 years, whereas the 2021 USPSTF recommendations’ eligible cohort included those
aged 50 to 80 years who had at least a 20 pack-year smoking history and currently smoked or quit
within the past 15 years. The 2021 eligible population also included individuals who were newly
eligible under the expanded recommendations (eg, those aged 50-55 years and with a 20-29 packyear smoking history). The 2021 newly eligible cohort represents the nonoverlapping comparator
group compared with the 2013 USPSTF recommendations cohort.
Sensitivity analyses included individuals with incomplete smoking history (eg, only age-eligible
current and previous smokers). To examine the potential increase in lung cancer identification by
screening, we used site-level cancer registry data to identify patients aged 50 to 80 years with an
incident lung cancer diagnosis between January 1, 2014, and September 30, 2019.

Statistical Analysis
We described the distributions of age, sex, tobacco use, race and ethnicity, Charlson Comorbidity
Index,16 chronic obstructive pulmonary disease diagnosis, SES (measured by the Yost Index17,18), and
previous cancer for the 2013 and 2021 USPSTF recommendations’ eligible cohorts and for the
nonoverlapping comparator group that would be newly eligible under the 2021 criteria. We described
the relative changes in these variables in both the newly eligible population and the overall 2021
eligible cohort. Differences in the distribution of variables between the 2013 and newly eligible 2021
cohorts were evaluated with 2-sided χ2 tests. A 2-sided P < .05 was considered statistically
significant. Analyses were performed with SAS statistical software, version 9.4 (SAS Institute Inc).
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Results
On September 30, 2019, we identified 1 428 423 individuals aged 35 to 89 years who received care
within the 5 health care systems in the PROSPR Lung Consortium (Figure). Limiting the population to
individuals who had 12 or more months of continuous enrollment or engagement, were between 50
and 80 years of age, and currently or previously smoked tobacco resulted in a population of 341 163
(eTable in the Supplement). Further limiting this population to those aged 55 to 80 years and
applying the tobacco history exclusions yielded a final eligible cohort under the 2013 USPSTF
recommendations of 34 528 individuals. The 2021 USPSTF recommendations added 18 533
individuals who were eligible for lung cancer screening for a total of 53 061 individuals, which was a
relative increase of 53.7% compared with the 2013 USPSTF recommendations (Figure).
Table 1 describes the individual-level characteristics of the eligible cohorts for the 2013 and
2021 USPSTF recommendations as well as the newly eligible cohort under the 2021 USPSTF

Figure. Profile of Individuals in the Population-based Research to Optimize the Screening Process (PROSPR)
Lung Consortium Population and Eligibility for Lung Cancer Screening (LCS) Under the 2013 and 2021
US Preventive Services Task Force (USPSTF) Recommendations Cohorts
1 428 423 Individuals in the PROSPR Lung
Consortium identified
137 954 Excluded for having less than 12 mo
of continuous enrollment/
engagement

1 290 469 With 12 mo of continuous
enrollment/engagement identified
454 825 Excluded for being younger than
50 y or older than 80 y

835 644 Individuals aged 50-80 y
identified
433 153 Excluded for never having used
tobacco
61 328 Excluded for unknown tobacco
use history
341 163 With current or previous tobacco use
identified
185 605 With unknown pack-years
or quit-year data
155 558 With known pack-years
and quit-year data

49 882 Individuals aged 50-54 y excluded

291 281 Individuals aged 55-80 y and with
current or previous tobacco use
identified
155 499 With unknown pack-years
or quit-year data
135 782 With known pack-years or
quit-year data

18 533 Additional individuals identified as
eligible for LCS under the 2021
USPSTF recommendations

34 528 Individuals identified as eligible for
LCS under 2013 USPSTF
recommendations

53 061 Individuals identified as eligible for
LCS under the 2021 USPSTF
recommendations
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recommendations (nonoverlapping population). The 2021 newly eligible population included 5833
individuals (31.5%) aged 50 to 54 years, a larger proportion of women than men (52.0% [n = 9631]
vs 48.0% [n = 8901]), and more racial or ethnic minority groups than the 2013 cohort. The relative
increase for women was 13.8% higher than for men (61.2% vs 47.4%). The relative increase by race
and ethnicity in the screening eligibility was 20.7% for non-Hispanic Black individuals compared with
non-Hispanic White individuals (69.7% vs 49.0%). Similarly, the relative eligibility increase for
Hispanic individuals was 18.4% (67.4% vs 49.0%) and for Asian, Hawaiian, or Pacific Islander
individuals was 11.6% (60.6% vs 49.0%) compared with non-Hispanic White individuals.
The 2021 newly eligible population had less comorbid illness, with the greatest relative increase
of 68.7% in individuals with a Charlson Comorbidity Index score of 0. Similarly, the proportion of
individuals with a diagnosis of chronic obstructive pulmonary disease in the newly eligible cohort was

Table 1. Characteristics of Eligible Cohorts Under the USPSTF 2013 and 2021 Lung Cancer
Screening Recommendations

Characteristic

2013 USPSTF
recommendations’
eligible cohort,
No. (%)a

2021 USPSTF
recommendations’
newly eligible
Relative
cohort, No. (%)b
P valuec increase, %

Overall 2021 USPSTF
recommendations’
eligible cohortb

Total

34 528

18 533

53.7

53 061

50-54

0

5833 (31.5)

NA

5833 (11.0)

55-59

6922 (20.0)

3052 (16.5)

44.1

9974 (18.8)

60-64

8905 (25.8)

3356 (18.1)

37.7

12 261 (23.1)

65-74

14 598 (42.3)

4869 (26.3)

33.4

19 467 (36.7)

75-80

4103 (11.9)

1423 (7.7)

34.7

5526 (10.4)

Female

15 734 (45.6)

9631 (52.0)

Male

18 794 (54.4)

8901 (48.0)

1939 (5.6)

1174 (6.3)

Age at time of eligibility, y

<.001

Sex
<.001

61.2

25 365 (47.8)

47.4

27 695 (52.2)

60.6

3113 (5.9)

Race and ethnicity
Asian, Native Hawaiian,
or Pacific Islander
Hispanic

1279 (3.7)

862 (4.7)

Multirace, other race,
or unknown raced

1750 (5.1)

979 (5.3)

Non-Hispanic Black

4929 (14.3)

3437 (18.5)

69.7

8366 (15.8)

Non-Hispanic White

24 631 (71.3)

12 081 (65.2)

49.0

36 712 (69.2)

0

14 608 (42.3)

10 039 (54.2)

68.7

24 647 (46.5)

1

7290 (21.1)

3515 (19.0)

48.2

10 805 (20.4)

2

4708 (13.6)

2021 (10.9)

42.9

6729 (12.7)

≥3

7922 (22.9)

2958 (16.0)

7720 (22.4)

2238 (12.1)

Q1

6228 (18.0)

Q2

6273 (18.2)

Q3

7215 (20.9)

3717 (20.1)

Q4

7406 (21.4)

3708 (20.0)

Q5

6477 (18.8)

Missing data

<.001

67.4

2141 (4.0)

55.9

2729 (5.1)

Charlson Comorbidity Index
score

<.001

37.3

10 880 (20.5)

29.0

9958 (18.8)

3804 (20.5)

61.1

10 032 (18.9)

3570 (19.3)

56.9

9843 (18.6)

51.5

10 932 (20.6)

50.1

11 114 (20.9)

3214 (17.3)

49.6

9691 (18.3)

929 (2.7)

520 (2.8)

56.0

1449 (2.7)

1

8244 (23.9)

4143 (22.4)

50.3

12 387 (23.3)

2

2511 (7.3)

1384 (7.5)

55.1

3895 (7.3)

3

14 202 (41.1)

7368 (39.8)

51.9

21 570 (40.7)

4

6837 (19.8)

3627 (19.6)

53.0

10 464 (19.7)

5

2734 (7.9)

2011 (10.9)

73.6

4745 (8.9)

COPD diagnosis

<.001

Yost Index quintiles

<.001

Center or site

<.001
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Abbreviations: COPD, chronic obstructive pulmonary
disease; NA, not applicable; USPSTF, US Preventive
Services Task Force.
a

Participants aged 55 to 80 years with a history of 30
pack-years and current smoker or quit smoking
within past 15 years.

b

Participants aged 50 to 80 years with a history of 20
pack-years and current smoker or quit smoking
within past 15 years.

c

Pearson χ2 test of difference in characteristic
distribution for people added under 2021 criteria vs
2013 criteria.

d

Multirace was a self-reportable option in the
electronic health data. Other was an explicit race
category available for reporting in one or more of the
Healthcare Systems included in this study.
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12.1%, resulting in a decrease in the overall prevalence of chronic obstructive pulmonary disease from
22.4% (n = 7720) in the 2013 eligible cohort to 18.8% (n = 9958) in the 2021 cohort. In addition, the
2021 USPSTF recommendations were associated with a greater increase in newly eligible individuals
in the lowest SES category. Specifically, 3804 newly eligible individuals (20.5%) were identified in
Yost Index quintile 1 (lowest SES) compared with 3214 individuals (17.3%) within quintile 5 (highest
SES), resulting in a relative increase of 61.1% for quintile 1 and 49.6% for quintile 5 (Table 1).
The sensitivity analysis that included all age-eligible individuals who currently or previously
smoked also demonstrated significant and consistent changes in the distribution of the expanded
eligibility for lung cancer screening by sex, race and ethnicity, and comorbidity status from those in
the 2013 USPSTF recommendations cohort, but the differences were less pronounced (eTable in the
Supplement). For example, the relative increase by race and ethnicity in the screening eligibility was
2.1% for non-Hispanic Black individuals compared with non-Hispanic White individuals (17.1%
vs 16.9%).
Table 2 describes the characteristics of patients who were diagnosed with an incident lung
cancer between January 1, 2014, and September 30, 2019, met the 2013 USPSTF recommendations,
and theoretically would be newly eligible under the 2021 criteria, and the overall cohort who met the
2021 USPSTF criteria. Under the 2021 USPSTF recommendations for expanded eligibility, the
identification of incident lung cancers increased by 30.0% (n = 379) compared with the 2013
USPSTF recommendations (n = 1265). The increase in lung cancer identification was most
pronounced among women, racial and ethnic minority groups, and those with lower SES. For
example, the largest relative increase (47.0%) by race and ethnicity was observed in non-Hispanic
Black individuals, whereas the smallest increase (26.2%) occurred among non-Hispanic White
individuals.

Table 2. Lung Cancer Cases Diagnosed in the PROSPR Lung Consortium Population Who Met the USPSTF 2013
and 2021 Lung Cancer Screening Recommendations

Relative
increase, %

Overall 2021 USPSTF
recommendations’
eligible cohort,
No. (%)b

379

30.0

1644

0

58 (15.3)

NA

58 (3.5)

126 (10.0)

38 (10.0)

30.2

164 (10.0)

60-64

253 (20.0)

54 (14.2)

21.3

307 (18.7)

65-74

636 (50.3)

162 (42.7)

25.5

798 (48.5)

75-80

250 (19.8)

67 (17.7)

26.8

317 (19.3)

Female

632 (50.0)

229 (60.4)

36.2

861 (52.4)

Male

633 (50.0)

150 (39.6)

23.7

783 (47.6)

Asian, Native Hawaiian,
or Pacific Islander

81 (6.4)

27 (7.1)

33.3

108 (6.6)

Hispanic

40 (3.2)

11 (2.9)

27.5

51 (3.1)

Non-Hispanic Black

185 (14.6)

87 (23.0)

47.0

272 (16.5)

Non-Hispanic White

925 (73.1)

242 (63.9)

26.2

1167 (71.0)

Multirace, other race,
or unknown raced

34 (2.7)

12 (3.2)

35.3

46 (2.8)

1

484 (38.3)

145 (38.3)

30.0

629 (38.3)

2

369 (29.2)

109 (28.8)

29.5

478 (29.1)

3

117 (9.2)

35 (9.2)

29.9

152 (9.2)

4

44 (3.5)

10 (2.6)

NA

54 (3.3)

5

251 (19.8)

80 (21.1)

31.9

331 (20.1)

Characteristic

2013 USPSTF
recommendations’
eligible cohort,
No. (%)a

2021 USPSTF
recommendations’
newly eligible
cohort, No. (%)b

Total

1265

50-54
55-59

P valuec

Age group, y

<.001

Sex
<.001

Race and ethnicity

.003

Center or site

.93
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Abbreviations: NA, not applicable; PROSPR,
Population-based Research to Optimize the Screening
Process; USPSTF, US Preventive Services Task Force.
a

Participants aged 55 to 80 years with a history of 30
pack-years and current smoker or quit smoking
within past 15 years.

b

Participants aged 50 to 80 years with a history of 20
pack-years and current smoker or quit smoking
within past 15 years.

c

Pearson χ2 test of difference in characteristic
distribution for people added under the 2021 criteria
vs 2013 criteria.

d

Multirace was a self-reportable option in the
electronic health data. Other is an explicit race
category available for reporting in one or more of the
Healthcare Systems included in this study.
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Discussion
To our knowledge, this study is the first in the community-based health care setting to examine both
population and cancer identification changes associated with the 2021 USPSTF expansion of the lung
cancer screening eligibility criteria. Consistent with the CISNET simulation and other studies,8,9,11,19
we estimated whether the increase in lung cancer screening eligibility under the 2021 USPSTF
recommendations was larger for women than men; individuals in lower SES categories; and
individuals who self-identified as having Asian, Native Hawaiian, or Pacific Islander, Hispanic, or
non-Hispanic Black rather than non-Hispanic White race or ethnicity. We identified similar increases
by sex, race and ethnicity, and SES in the proportion of patients with lung cancer who were eligible
for screening under the 2021 USPSTF recommendations. Although estimates from the 2015
nationally representative survey data suggested that the 87% increase in eligibility was attributable
to the 2021 recommendations,11 our estimates, which used EHR-derived demographic and clinical
measures for patients in the PROSPR Lung Consortium cohort, suggested an overall eligibility
increase of 53.7%. However, the methods and data sources used in the present evaluation of the
2021 USPSTF recommendations expansion differed substantially from those used by CISNET and
other survey-based studies.
The findings of this study, in conjunction with those of CISNET, also indicated that health care
systems should plan to increase lung cancer screening capacity by about 50% to 60% to
accommodate the eligible cohort of the expanded 2021 recommendations. Considerations for
adding lung cancer screening capacity should include screening coordinators to provide shared
decision-making and manage future screening and evaluation, access to computed tomography
scans and trained radiologists, and constraints related to access to thoracic surgeons for lung cancer
resection surgery.20 Improvements in uptake and adherence to annual screening also play a role in
increasing this capacity. Screening programs will need to closely monitor capacity strain and allocate
resources appropriately to meet evolving demands as the 2021 USPSTF recommendations are
adopted in clinical practice.
Findings of the present study suggest that expanding the USPSTF recommendations for lung
cancer screening eligibility is an important step toward minimizing disparities in lung cancer
screening, but health care systems will still need to invest substantial resources to tailor outreach
strategies and reduce barriers to lung cancer screening uptake for those with lower SES and for racial
and ethnic minority groups. Ultimately, the value of the expanded guidelines will be realized only if
lung cancer screening rates are increased in high-risk and traditionally underserved populations,
particularly among non-Hispanic Black individuals, who have some of the highest rates of lung cancer
mortality in the US.

Limitations
This study has several limitations. First, the PROSPR Lung Consortium cohort included a high
proportion of current or former smokers whose EHR data did not capture pack-years and cessation
date. This missing information reflects real-world health care system data capture on these
components of lung cancer screening eligibility and highlights the need for clinician and system
incentives to improve information capture to ascertain eligibility.21 This issue may be particularly
relevant for underserved populations, those with lower health care use, and former smokers for
whom the identification of smoking history is key to establishing eligibility.
Second, we used the Yost index, a well-validated, composite Census tract proxy for SES rather
than self-reported measures of income, wealth, or other key social determinants of health to identify
the potential economic, financial, or resource-based disparities associated with the 2021 USPSTF
recommendations.
Third, we did not address the potential benefits and harms of the expanded eligibility for lung
cancer screening within and across the PROSPR Lung Consortium. Specifically, we did not examine
the potential changes per-screen rate of false-positives that were associated with the 2021 USPSTF
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recommendations. Currently, no US data are available on false-positive rates in the expanded patient
population (aged 50-54 years or with less tobacco history), making it difficult to estimate the falsepositives with any certainty. The CISNET modeling estimate for per-screen rate of false-positives for
the 2021 USPSTF recommendations was 11.86%,11 which was consistent with the 2013 USPSTF
recommendations’ eligibility estimates of 12.8% from the NLST22 and 10.4% from an analyses of a
diverse, urban, underserved, community-based lung cancer screening program.23 Despite these
limitations, the dynamic and frequently updated data infrastructure of the PROSPR Lung
Consortium, which is based on individuals who receive health care services in community settings,
provided insight into how the 2021 USPSTF recommendations may help reduce the disparities
among individuals who are eligible for lung cancer screening in the United States.

Conclusions
This cohort study showed that the 2021 USPSTF recommendations were associated with increased
lung cancer screening eligibility of women, racial and ethnic minority individuals, and those with
lower SES who were eligible for such a screening. This updated eligibility criteria may help reduce
barriers to screening access for individuals at highest risk for lung cancer.
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